Can a common bile acid pill speed recovery from hepatitis?
NCT ID NCT07525401
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a medicine called ursodeoxycholic acid (UDCA) can help lower bilirubin levels in people with acute viral hepatitis (types A or E). Bilirubin is a waste product that builds up when the liver is inflamed, causing jaundice. The trial will compare 88 adults who get UDCA plus standard supportive care against those who get supportive care alone, measuring bilirubin changes after 7 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE VIRAL HEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Booster shot hope: extra hepatitis a vaccine studied for thai kids
- One shot enough? thai kids' hepatitis a immunity tested years later
- Do childhood vaccines last? 5-year follow-up study launched in china
- 10,000 people tested: Cambodia's massive disease hunt begins
- HIV patients get hepatitis a vaccine: does it work?